bioAffinity Technologies, Inc.
BIAFHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframebioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company carries a $4.4M market cap, placing it firmly in the micro-cap category. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
Market Cap
$4.4M
Beta
-1.11
P/E (TTM)
—
P/E (Fwd)
-1.18
EPS (TTM)
$-4.70
EPS (Fwd)
$-0.60
ROE
-622.6%
ROA
-107.1%
Cash
$3.1M
Total Debt
$1.4M
Free CF
-$6.1M
52W Change
-93.2%
Annual Financials
Cash vs Debt
Where BIAF stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, BIAF finished 58.48% below its 150-day moving average ($1.71) and 62.03% below its 200-day moving average ($1.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIAF overbought or oversold?
At the July 15, 2026 close, BIAF's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
bioAffinity Technologies, Inc. holds $3.1M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -622.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5K (2022) to $6.1M (2025), reflecting a 127070% increase over the period.
With a beta below 0.7, bioAffinity Technologies, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, BIAF has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BIAF's risk profile alongside its fundamentals and technical indicators provides a more complete picture.